If you or someone you love is managing osteoporosis in China, the advice you get may depend heavily on which guideline your doctor happens to follow. A new systematic review looked at 13 Chinese clinical practice guidelines for osteoporosis and scored them using two standard tools: AGREE II, which measures how well a guideline was built, and AGREE-REX, which measures how trustworthy its recommendations are.
The results were mixed. The median overall quality score was 54%, with scores ranging from 49% to 71%. The weakest area by far was rigor of development, which scored a median of just 38% and dipped as low as 25% in some guidelines. That domain covers things like how thoroughly evidence was gathered and how clearly it was linked to recommendations. The strongest areas were stakeholder involvement and clarity of presentation, both scoring a median of 72%.
Recommendation quality, measured by AGREE-REX, came in at a median of 56%, with a wide range from 32% to 63%. The two scoring systems moved together: guidelines that scored higher on AGREE II also tended to score higher on AGREE-REX, with a positive correlation of r = 0.665.
A few things to keep in mind. This review assessed the guidelines themselves, not patient outcomes, so it cannot tell you whether following one guideline leads to better bone health than another. The authors also note that recommendations on functional assessment, diet and exercise, rehabilitation, and environmental changes stood out as valuable, and that traditional Chinese medicine exercises might offer a useful reference for guideline developers in other countries. No funding or conflict of interest information was reported.
